
|Videos|April 9, 2013
Episode 3 - The Diversity of Patient Populations
Advertisement
Episodes in this series

Many of the comorbid cardiometabolic disorders are tied to complex, multifaceted, and oftentimes overlapping origins. Such is the case of obesity, which in many patients, is the precursor to diabetes. While certain regions of the US, such as the south and southeast, tend to experience a higher prevalence of obesity and diabetes, these disorders are rooted in various behavioral, environmental, and genetic components. As such, the management of these comorbid conditions is often complicated. However, with advancing technology, improving drug pipelines, and evolving clinical practice guidelines, the healthcare and managed care communities are becoming better equipped to tackle the burden of comorbid cardiometabolic diseases.
Advertisement
Related to this article

Vitamin K shot refusals rose 77% from 2017 to 2024. Experts break down the drivers, risks, and how clinicians and payers should respond in 5 FAQs.

Oral GLP-1s, Medicare access, and lingering weight bias are reshaping obesity care, says NYU Langone's Holly Lofton, MD.

ERS spotlights AI lung disease detection; employer cancer benefits; outpatient CAR T; tafasitamab response similar across races; HFpEF missed at referral.

Working-age adults with private insurance are paying off medical debt, often draining savings, delaying care, or cutting back on necessities as a result.

Finerenone is the first new FDA-approved treatment in more than 30 years for adults with CKD associated with type 1 diabetes.

Women with endometriosis have a 46% higher type 2 diabetes risk, highest among premenopausal, non-obese women, study finds.

Community oncology leaders urge 340B overhaul so drug discounts follow vulnerable cancer patients, with audits, transparency, and tighter contract-pharmacy rules. This commentary will be featured on the Cover of the October issue of Evidence-Based Oncology.
Advertisement
Advertisement
Trending on AJMC
1
Delayed Dupilumab Raises Asthma Costs 32%: Nicola Hanania, MD
2
Regorafenib Prescribing in Advanced GIST Deviates From Guidelines
3
Which Antibiotics Raise C. Diff Risk Most? Jason Pogue, PharmD
4
FDA Expands Finerenone Approval to CKD Associated With Type 1 Diabetes
5

























